Revenue grew 11% year-over-year to 27.9 MSEK, with a positive net income and strengthened equity. Major contracts, AI integration, and clinical study milestones position the company for continued growth and stable cash flow in 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.